Dr. Kelly C. Lee: Neuropsychiatry, Medication Therapy Management, Pharmacogenomics

Research Summary: Neuropsychiatry, Medication Therapy Management, Pharmacogenomics

Dr. Lee’s research program involves the effective use of psychotropic medications in the mental health setting using both basic and clinical scientific tools. She is currently involved in studying the pharmacogenomic variations that may predict treatment response and remission from medications among patients with treatment-resistant depression and bipolar disorder. She is also one of the Co- Investigators of an educational campaign project (Pharmacogenomics Education Program™) that strives to educate health care professionals and students about pharmacogenomic concepts and clinical applications.

Dr. Lee also conducts research on the appropriate utilization of psychotropic medications and the impact of pharmacist services in mental health settings. She is currently studying the effect of pharmacist-run medication management services on the metabolic monitoring of psychotropic medications. Dr. Lee maintains a Medication Therapy Management (MTM) clinic at the UCSD Outpatient Psychiatric Services.

Academic Achievements

Education: B.S. in Biology (1996) UCLA; Pharm.D. (2000) UCSF; ASHP-Accredited Residency in Pharmacy Practice and Fellowship in Behavioral Health Sciences (2000-2003) UCSF; Board Certification in Psychiatric Pharmacy (2004) (BCPP).

Awards and Honors: Career Development Research award from ACCP (2008); Minisabbatical award from the Central Nervous System (CNS) Practice and Research Network (PRN) of ACCP (2005); Dorfman Best Article for Original Research Award, (2007); Preceptor of the Year, Loma Linda Univ. (2006); Rho Chi Honor Society (2004); Phi Lambda Sigma National Pharmacy Leadership Society (2000).

Leadership Experience: Chair, CNS PRN of ACCP (2009-2010); Director, PharmGenEd™ Training for Health Professional Schools (2010); President, Southern California chapter of ACCP (2006); Program Chair, College of Psychiatric and Neurologic Pharmacists Annual Meeting (2008-2009).

Teaching

• Therapeutics (SPPS 212C)
• Pharmacy Practice (SPPS 201, 202)
• Pharmacogenomics (SPPS 219)
• APPE Ambulatory Care – Psychiatry MTM

Key Contributions to Pharmaceutical Sciences

• Effective use of psychotropic medications among patients with severe mental illness.
• Established the MTM clinic at the UCSD Outpatient Psychiatric Services.
• Clinical research in psychotropic medication utilization in mental health settings (inpatient, outpatient, community, government, academic centers).
• Pharmacogenomics studies in patients with mood disorders.

Selected Recent Publications

Lee et al. (2005). Treatment response and dshort- term outcome in patients with status epilepticus and HIV. Neurology 65:314-16.

Lee et al. (2007). Tamoxifen treatment and new- onset depression in breast cancer patients. Psychosomatics 48:205-210.

Gilmer et al. (2009). Adherence to antipsychotics among Latinos and Asians with schizophrenia and limited English proficiency. Psychiatry Serv. 60:175- 182.

Lee et al. (2010). Pharmacogenomics: Bridging the gap between science and practice. JAPhA. 50e:e1- e17.

Potential Collaborative Programs with the Pharmaceutical Industry

• Identifying biologic targets for treatment-resistant depression and novel antidepressant agents that will optimize treatment remission.
• Developing service interventions that will improve utilization of psychotropic medications among patients with severe mental illness.
• Developing novel practice models that will improve the course of treatment of patients with severe mental illness.